Infectious Diseases News and Research

RSS

Government orders additional H1N1 vaccine

Associated Press/Boston Globe reports that on Monday, "the United States ordered more swine flu vaccine, bringing its eventual total to 251 million doses, up from the long-planned 195 million doses.

23 Sep 2009

ONA appeals against Ministry of Labour's decision in London nurse's death investigation

The Ontario Nurses' Association (ONA) is appealing the decision by a Ministry of Labour inspector to not issue orders against London Health Sciences Centre or make recommendations for improvements in procedures and practices following the death of one of its registered nurses of methicillin-resistant staphylococcus aureus (MRSA).

22 Sep 2009

Advaxis' patent approval enables the development of new vaccines with additional properties

The United States Patent and Trademark Office (USPTO) has granted and issued Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, patent 7,588,930 “Compositions and Methods for Enhancing Immunogenicity of Antigens.” This patent expands the Company’s intellectual property portfolio to cover another family of adjuvant proteins based upon the Lm protein Act-A.

22 Sep 2009

Updates from Pacific Biosciences to its commercial strategy and progress

Pacific Biosciences, a private company developing a disruptive technology platform for real-time detection of biological events at single molecule resolution, today provided a number of updates to its commercial strategy and progress.

22 Sep 2009

Major shift in cancer research priorities needed

Cancer research is too focused on new drug development, while not enough money and effort is being devoted to pursuing important advances in knowledge likely to have the biggest impact on combating the disease in the next few decades, a leading research policy expert says, adding that a major shift in research priorities will be crucial to the ability to cope with the coming wave of cancer cases.

22 Sep 2009

U.S. HHS orders for an additional 29 million doses of MedImmune's influenza vaccine

MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has placed an order for an additional 29 million doses of its live attenuated influenza vaccine (LAIV) against the 2009 H1N1 influenza virus. This brings HHS orders to date to more than 40 million vaccine doses, with a total cumulative contract value of approximately $453 million.

22 Sep 2009

Results from a trial testing a 2009 H1N1 influenza vaccine in children look promising

Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

22 Sep 2009

Biochemists are developing a new system to better understand antibiotic resistance

Rice University biochemists are developing a system of "evolutionary forecasting" to better understand the mechanisms of antibiotic resistance.

22 Sep 2009

Duke University awarded $19.5M to design a portable viral infection detection device

The Defense Advanced Research Projects Agency (DARPA), the research arm of the U.S. Department of Defense, has awarded Duke University $19.5 million for an effort led by the Duke Institute for Genome Sciences & Policy (IGSP) to design a portable, easy-to-use diagnostic device that can reveal who is infected with an upper respiratory virus before the first cough or sneeze.

22 Sep 2009

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that it has been awarded an approximate $9.4 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

21 Sep 2009

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Antigen Discovery, Inc. ("ADi", formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009.

21 Sep 2009

Vaccine Global Congress organized by Elsevier's Vaccine journal

Elsevier, a leading publisher of scientific, technical and medical information products and services, announced today, that its journal Vaccine, the most comprehensive and pre-eminent journal for those interested in vaccines and vaccination, will organize the 3rd Vaccine Global Congress from 4-6 October, 2009, in Singapore.

21 Sep 2009

Recent releases: Climate change, health; ITNS; Mexico H1N1; Policy Tracker; TB treatment; blogs

In addition to the Lancet's recent publication of an opinion piece and letter by 18 doctor association leaders about the potential health risks associated with climate change, the journal includes an editorial about sexual and reproductive health and climate change and a comment on the upcoming Copenhagen conference in December (9/19).

21 Sep 2009

Single inoculation for rabies vaccination

...

21 Sep 2009

H1N1 infected people continue to shed live virus days after the symptoms

ABC News and other outlets are reporting that two studies released on Tuesday suggest that people infected with the H1N1 virus continue to shed virus after the point where current recommendations say they can resume their normal activities.

19 Sep 2009

Health experts to discuss innovative breakthroughs to solve health issues in poor communities

New ideas, systems and technologies are emerging to solve numerous health challenges facing the world’s poorest communities. Some of the foremost experts on global health will discuss these and the prospects for health breakthroughs in the developing world at a media briefing at the Conrad N. Hilton Humanitarian Symposium at 2:30 pm on Monday, September 21.

19 Sep 2009

Partnership between Wellcome Trust and Merck & Co

The Wellcome Trust and Merck & Co., Inc. today announced the creation of the MSD Wellcome Trust Hilleman Laboratories (www.hillemanlaboratories.in), the first of its kind research and development joint venture with a not-for-profit mission to focus on developing affordable vaccines to prevent diseases that commonly affect low-income countries.

18 Sep 2009

National Institutes of Health funds for thymus research

The National Institutes of Health have awarded, as part of the American Reinvestment and Recovery Act, a two-year, $2 million grant to a University of Georgia genetics researcher and her colleagues for studies on the thymus, the organ in humans that produces disease-fighting T-cells.

18 Sep 2009

Juvaris BioTherapeutics completes first close on Series B equity financing

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed the first close on its Series B equity financing of up to $25 million led by SV Life Sciences (SVLS) along with existing investor, Kleiner Perkins Caufield & Byers (KPCB).

18 Sep 2009

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

18 Sep 2009

Infectious Diseases News and Research

Government orders additional H1N1 vaccine

ONA appeals against Ministry of Labour's decision in London nurse's death investigation

Advaxis' patent approval enables the development of new vaccines with additional properties

Updates from Pacific Biosciences to its commercial strategy and progress

Major shift in cancer research priorities needed

U.S. HHS orders for an additional 29 million doses of MedImmune's influenza vaccine

Results from a trial testing a 2009 H1N1 influenza vaccine in children look promising

Biochemists are developing a new system to better understand antibiotic resistance

Duke University awarded $19.5M to design a portable viral infection detection device

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Vaccine Global Congress organized by Elsevier's Vaccine journal

Recent releases: Climate change, health; ITNS; Mexico H1N1; Policy Tracker; TB treatment; blogs

Single inoculation for rabies vaccination

H1N1 infected people continue to shed live virus days after the symptoms

Health experts to discuss innovative breakthroughs to solve health issues in poor communities

Partnership between Wellcome Trust and Merck & Co

National Institutes of Health funds for thymus research

Juvaris BioTherapeutics completes first close on Series B equity financing

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

eBook: Advancing infectious disease vaccine development eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News